Vietnam Vaccine JSC (VNVC) and Sanofi (France) have announced a major step forward in their partnership to produce next-generation vaccines in Vietnam starting in 2028.
The announcement was made during the Vietnam-France High-Level Conference held on July 9, co-organized by the Ministry of Health of Vietnam and the French Embassy. The conference theme focused on "Strengthening cooperation to deploy strategic technologies and strategic technology products for next-generation vaccine development in Vietnam."
Under the agreed roadmap, VNVC and Sanofi will collaborate to produce several essential, high-demand vaccines for both children and adults at the VNVC Vaccine and Biologicals Factory. Sanofi’s first key next-generation vaccines are expected to be produced in Vietnam starting in 2028.
During the event, VNVC updated the progress of its Vaccine and Biologicals Factory and the portfolio of next-gen vaccines prioritized for production to meet high-quality immunization needs in Vietnam. The facility is scheduled to be operational by late 2027, begin production in 2028, and launch commercial products by 2029.
VNVC aims to become a leading regional hub for research, technology transfer, production, and testing of high-tech vaccines and biologicals. Its high-tech factory will serve as a foundation for international technology cooperation, while its modern Research Institute is designed to attract scientific studies for new vaccine types.
"We look forward to breakthrough mechanisms and policies that encourage businesses to invest in strategic technology products," said Mr. Ngo Chi Dung, Chairman and CEO of VNVC. "This will help the public access high-tech vaccines sooner and at more affordable prices, while gradually ensuring domestic supply and strengthening national health security."
The VNVC Vaccine and Biologicals Factory, located in southern Tay Ninh province, represents an initial investment of over VND2.5 trillion (approx. $95 million).
Covering more than 26,000 sq.m, the plant is designed to meet EU-GMP, WHO-GMP, and US-FDA standards, with a production capacity of approximately 100 million doses per year.
Google translate